Production of infectious HCV genotype 1b virus in cell culture using a novel Set of adaptive mutations.
BACKGROUND
Despite the high prevalence of genotype 1b hepatitis C virus (HCV) among patients, a cell culture system that permits entire viral life cycle of genotype 1b isolates is limited. To develop a cell-cultured hepatitis C virus (HCVcc) of genotype 1b, the proper combination of HCV genomic variants and host cells is essential. HCV genomes isolated from patients with distinctive symptoms may provide the variants required to establish an HCVcc of genotype 1b.


RESULTS
We first established subgenomic replicons in Huh7 cells using HCV cDNAs isolated from two patients: one with fulminant hepatitis after liver transplantation (TPF1) and another with acute hepatitis and moderate symptoms (sAH). Replicons established from TPF1 and sAH showed mutations in NS4B and in NS3 and NS5A, respectively. Using these replication machineries, we constructed HCV genomic RNAs for each isolate. Virus infectivity was evaluated by a focus-forming assay, which is dependent on the intracellular expression of core antigen, and production of virus particles was assessed by density-gradient centrifugation. Infectious virus was only observed in the culture medium of cells transfected with TFP1 HCV RNA. A chimeric genome with the structural segment (5'-untranslated region [UTR] through NS2) from sAH and the replication machinery (NS3 through 3'-UTR) from TPF1 exhibited greater infectivity than did TFP1, despite formation of deficient virus particles in sAH, suggesting that this genomic segment potentiates virus particle formation. To identify the responsible variants, infectious virus formation was assessed in a chimeric genome carrying parts of the sAH structural segment of the TPF1 genome. A variant in NS2 (M170T) was identified that enhanced infectious virus formation. HCVcc carrying an NS2 gene encoding the M170T substitution and adaptive mutations in NS4B (referred to as TPF1-M170T) infected naïve cured Huh7 cells in a CD81-dependent manner.


CONCLUSIONS
We established a novel HCVcc of genotype 1b in Huh7 cells by introducing an amino acid variant in NS2 and adaptive mutations in NS4B from HCV genomic RNA isolated from a patient with fulminant HCV after liver transplantation.
R&D Department, Advanced Life Science Institute, Inc., 2-10-23 Maruyamadai, Wako, Saitama, 351-0112, Japan.
Ken-Ichi
KI
Mori
Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Akihiro
A
Matsumoto
R&D Department, Advanced Life Science Institute, Inc., 2-10-23 Maruyamadai, Wako, Saitama, 351-0112, Japan.
Noboru
N
Maki
Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Yuki
Y
Ichikawa
Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Eiji
E
Tanaka
R&D Department, Advanced Life Science Institute, Inc., 2-10-23 Maruyamadai, Wako, Saitama, 351-0112, Japan. syagi@alsi-i.co.jp.
Shintaro
S
Yagi
Adapted mutation; Genotype 1b; HCV; HCVcc; NS2; NS4B
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2310-5
16461899
N Engl J Med. 1996 Jan 11;334(2):77-81
8531962
Curr Genet. 1993 Jul-Aug;24(1-2):12-20
8395354
Curr Top Microbiol Immunol. 2013;369:113-42
23463199
Hepatology. 2014 Dec;60(6):1838-50
24797787
Proc Natl Acad Sci U S A. 2012 May 1;109(18):E1101-10
22467829
Proc Natl Acad Sci U S A. 2006 May 9;103(19):7408-13
16651538
J Virol. 2012 Oct;86(19):10805-20
22787209
PLoS Pathog. 2011 Feb 10;7(2):e1001278
21347350
Hepatology. 2014 Feb;59(2):395-407
23913364
J Virol. 2007 Dec;81(23):13168-79
17881454
J Virol. 2008 Jul;82(14):7034-46
18480457
Nat Med. 2013 Jul;19(7):837-49
23836234
J Virol. 2008 Nov;82(21):10671-83
18715921
Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19757-62
23151512
J Virol. 2014 Feb;88(3):1433-46
24173232
Microbiol Immunol. 2007;51(4):471-82
17446688
Science. 1999 Jul 2;285(5424):110-3
10390360
PLoS Pathog. 2009 Jun;5(6):e1000475
19521536
J Med Virol. 2005 Nov;77(3):399-413
16173026
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4991-6
21383155
J Clin Microbiol. 1999 Jun;37(6):1802-8
10325327
Science. 2005 Jul 22;309(5734):623-6
15947137
Nat Med. 2010 Nov;16(11):1295-8
20935628
Clin Liver Dis. 2003 Feb;7(1):149-61
12691464
J Med Chem. 2014 Mar 13;57(5):1627-42
24164647
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8738-43
9238047
Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4370-5
18334634
J Virol. 2011 Jul;85(13):6464-79
21507970
J Virol. 2011 Jul;85(14):6963-76
21543474
J Virol. 2011 Feb;85(4):1706-17
21147927
J Virol. 2007 May;81(9):4591-603
17301154
Microbiol Immunol. 2012 May;56(5):308-17
22320232
J Virol. 2013 Dec;87(24):13297-306
24089562
J Virol. 2011 Sep;85(17):8913-28
21697486
J Virol. 2013 Jul;87(13):7409-22
23616661
Intervirology. 2005;48(6):372-80
16024941
Intervirology. 1994;37(2):87-100
7529222
Nat Med. 2014 Aug;20(8):927-35
25064127
Science. 2000 Dec 8;290(5498):1972-4
11110665
J Virol. 2007 Jan;81(2):629-38
17079282
J Biol Chem. 2005 Jun 10;280(23):21713-9
15814524
J Virol. 2009 Dec;83(24):12702-13
19812162
J Virol. 2007 Oct;81(19):10220-31
17634240
J Virol. 2011 Mar;85(6):2891-906
21177811
J Virol. 2013 Feb;87(3):1664-78
23175364
Hepatology. 2009 Feb;49(2):364-77
19148942
Nat Med. 2005 Jul;11(7):791-6
15951748
J Virol. 2014 Jun;88(11):6519-23
24648458
Virology. 1998 Apr 25;244(1):161-72
9581788
J Virol. 2003 Mar;77(5):3007-19
12584326
J Immunol Methods. 1996 Mar 28;190(1):79-89
8601714
J Virol. 2002 Dec;76(24):13001-14
12438626